Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares Antengene, A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies, NFKBIA, Angiocrine Bioscience and the tag heme.
Shares Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies, Glucocorticoid receptor (NR3C1), RPL10, Harmonise Europe's hospital exemption for academic cell therapies, with one registry and the tag heme.
Shares Akifumi Takaori, Martin Bornhäuser, JW Pharmaceutical, Mission Bio and the tag heme.
Shares A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies, A watch-and-wait registry for blood precursor conditions found by chance, BTG1, Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom and the tag heme.
Shares Glucocorticoid receptor (NR3C1), TUBA1A, TUBA1B, TUBA1C and the tag heme.
Shares SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer, HDAC5, HDAC7, HDAC8 and the tag heme.
Shares Plasmablastic lymphoma and the tag heme.
Shares Plasmablastic lymphoma and the tag heme.
The same record for scripts and assistants; checked 2026-09-07. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.